It is well known that antioxidants protect agents against adriamycin (Doxorubicin)-induced cardiotoxicity. However, the optimal agent or its optimal dose is still controversial. Aim of the work: to examine the possible ameliorative effects of vitamin E (in different doses) for adriamycin-induced cardiotoxic effects Methods: Fifty male rats were divided into 5 equal groups. Control rats received normal saline. Group (2): Rats received adriamycin (2 mg/kg) intraperitoneally every other day for 15 days. Group (3): rats received adriamycin as in group 2 and 100 mg Vitamin E/kg BW/day orally for 15 days. Groups (4) and (5): as in group 3, but vitamin E dose increased to 200 mg and 300 mg, respectively. CK, LDH, CK-MB, CAT, SOD, MDA, and GSH levels were measured. Finally, cardiac muscle histopathology was performed and documented. Results: Biochemical indicators increased, SOD, CAT, and GSH decreased, and MDA increased with adriamycin usage. In a dose-dependent way, vitamin E improved symptoms (the higher dose was associated with better improvement). Biochemical signs did not return to normal even with the greatest vitamin E intake. CK was strongly and negatively linked with SOD, CAT, and GSH but proportionally correlated with MDA. CK-MB correlated with LDH. Histopathological testing verifies these findings. Conclusion: Oxidative stress plays a significant role in adriamycin cardiotoxicity. Vitamin E in different doses ameliorated the cardiotoxic effects in a dose-dependent manner. Thus, concomitant administration of vitamin E could protect the heart and extend adriamycin's use as an anticancer agent.